Well I think you are wrong there IMO. There is no "equivocal...

Well I think you are wrong there IMO. There is no "equivocal result". It either successfully meets the primary end point for each trial or it fails to achieve the primary end point. Infact it probably has to achieve the primary endpoint in BOTH trials for the FDA to give approval to the treatment as a universal add on to any VEGF-A drug. So it really is a binary outcome. Success in one trial will likely lead only to approval for a combination therapy for that specific drug. If both trials are successful then as you say, everybody wins.

But the next milestone to be announced, hopefully next month is the completion of recruitment for both trials. That might see some further support for the share price.